OncoMatch/Clinical Trials/NCT04683653
Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
Is NCT04683653 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies non-drug interventions for endometrial cancer.
This study will investigate if a shorter treatment course (known as "hypofractionation") for pelvic radiation is safe for women with endometrial cancer. Doctors leading the study will also determine the safest and most tolerable dose of shortened radiation (hypofractionation) used to treat women in this study. Because this study will shorten the radiation course typically used to treat endometrial cancer, each daily treatment given to women in this study will be slightly higher than normal to ensure that the total radiation dose they receive is still effective and similar to the radiation dose they would receive if they were not participating in this study (standard treatment).
Check if I qualifyExtracted eligibility criteria
Cancer type
Endometrial Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: surgery — definitive
Cannot have received: radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Winship Cancer Institute, Emory University · Atlanta, Georgia
- University of Illinois at Chicago (UIC) · Chicago, Illinois
- University of Chicago · Chicago, Illinois
- MD Anderson Cancer Center · Houston, Texas
- Huntsman Cancer Institute · Salt Lake City, Utah
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify